The development of selective steroidal mineralocorticoid receptor antagonists with improved pharmacological profiles over existing marketed drugs is an attractive goal. Such compounds offer potential for the treatment of hypertension, heart failure and renal disease. With this aim, new spirolactones were prepared exploring substitutions at carbons 6, 7, 9-11, 15-16 and 21. Spirolactones 11 a and 20 were identified with promising biological profiles. Both compounds restored Na + /K + ratios to physiological levels in an in vivo model
Negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGlu 5 ) hold great promise for the treatment of a variety of central nervous system disorders. We have recently reported that prop-2ynylidenecycloalkylamine derivatives are potent and selective NAMs of the mGlu 5 receptor. In this work, we explored the amide, carbamate, sulfonamide, and urea derivatives of prop-2ynylidenecycloalkylamine compounds with the aim of improving solubility and metabolic stability. In silico and experimental analyses were performed on the synthesized series of compounds to investigate structure−activity relationships. Compounds 12, 32, and 49 of the carbamate, urea, and amide classes, respectively, showed the most suitable cytochrome inhibition and metabolic stability profiles. Among them, compound 12 showed excellent selectivity, solubility, and stability profiles as well as suitable in vitro and in vivo pharmacokinetic properties. It was highly absorbed in rats and dogs and was active in anxiety, neuropathic pain, and lower urinary tract models.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.